Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NSCLC, metastatic

LBA61 - First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Date

18 Sep 2020

Session

Mini Oral - NSCLC, metastatic

Presenters

Stephen Liu

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

S.V. Liu1, L.C. Villaruz2, V.H.F. Lee3, V.W. Zhu4, C.S. Baik5, A. Sacher6, C.E. McCoach7, D. Nguyen8, J.Y. Li9, J.M. Pacheco10, C. Kim1, T.F. Burns11, E.L. Schenk10, N. Leighl12, L. Tozzi13, D.R. Camidge14

Author affiliations

  • 1 Medical Oncology, Georgetown University, 20007 - Washington/US
  • 2 Medicine Hem/onc Department, UPMC Hillman Cancer Center, 15232 - Pittsburgh/US
  • 3 Department Of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong/HK
  • 4 Medicine, University of California - Irvine, 92868 - Orange/US
  • 5 Medical Oncology, Seattle Cancer Care Alliance, 98109 - Seattle/US
  • 6 Medical Oncology And Hematology Department, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 7 Medical Oncology, USCF Helen Diller Family Comprehensive Cancer Center, 94143 - San Francisco/US
  • 8 Medical Oncology, Pacific Shores Medical Group, 92618 - Irvine/US
  • 9 Department Of Clinical Oncology, Hong Kong United Oncology Centre, 999077 - Kowloon/HK
  • 10 Medical Oncology, University of Colorado, 80045 - Aurora/US
  • 11 Department Of Medicine, Division Of Hematology/oncology, University of Pittsburgh Medical Center Hillman Cancer Center, 15232 - Pittsburgh/US
  • 12 Medical Oncology Department, University Health Network - Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 13 Clinical Operations, Rain Therapeutics, 94560 - Neward/US
  • 14 Medical Oncology, University of Colorado Cancer Center, 80045 - Aurora/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA61

Background

Tarloxotinib is a hypoxia-activated prodrug of a pan-ErbB kinase inhibitor that releases a potent irreversible active metabolite (tarloxotinib-E) under hypoxic conditions to preferentially deliver the active moiety to tumor versus normal tissues. Tarloxotinib has shown preclinical efficacy in EGFR exon 20 and HER2 mutant non-small cell lung cancer (NSCLC) as well as other oncogenic alterations in the ERBB gene family such as NRG1 fusions. We report the first results of the RAIN-701 trial (NCT03805841).

Methods

Patients (pts) with advanced NSCLC harboring an EGFR Exon 20 insertion (Cohort A) or HER2 activating mutation (Cohort B) with progressive disease after platinum-based chemotherapy or with any solid tumors harboring an NRG1, EGFR, HER2 or HER4 fusion (cohort C) were eligible. Enrollment was based on local genomic testing. Tarloxotinib was administered at 150 mg/m2 IV weekly. The primary endpoint is objective response rate per RECIST v1.1.

Results

As of June 12, 2020, 23 pts (11 cohort A, 11 cohort B, 1 cohort C) were treated with tarloxotinib. The disease control rate for all evaluable pts was 60% (12/20). In cohort A, the best response was stable disease (SD) in 6/11 (55%) and progressive disease (PD) in 5/11 (45%). In cohort B, 4/9 evaluable pts (44%) exhibited tumor reduction by RECIST and 2/9 pts experienced confirmed PR (22%), 4/9 (44%) pts had SD, and 3/9 (33%) pts had PD. Three pts in cohort B were treated beyond 6 months with 3 pts still ongoing. Most treatment emergent adverse events (TEAEs) were grade 1/2. Those occurring at >20% were prolonged QTc (60.9%), rash (43.5%), nausea (21.7%), and diarrhea (21.7%). The grade 3 TEAEs were prolonged QTc (34.8%), rash (4.3%), diarrhea (4.3%) and increased ALT (4.3%). Five of 23 (21.7%) pts required dose reduction and only 1/23 (4.3%) pts discontinued tarloxotinib due to a drug-related adverse event (infusion reaction).

Conclusions

Tarloxotinib exhibits antitumor activity in NSCLC pts with HER2 activating mutations. Tarloxotinib was well tolerated and exhibited low rates of severe EGFR-related toxicities such as rash and diarrhea.

Clinical trial identification

NCT03805841.

Editorial acknowledgement

Legal entity responsible for the study

Rain Therapeutics.

Funding

Rain Therapeutics.

Disclosure

S.V. Liu: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Boehringer Ingehleim; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy: Catalyst; Advisory/Consultancy: Celgene; Advisory/Consultancy: G1 Therapeutics; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Genentech/Roche; Advisory/Consultancy: Guardant Health; Advisory/Consultancy: Inivata; Advisory/Consultancy: Janssen; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy: Loxo; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck/MSD; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Regeneron; Advisory/Consultancy: Takeda; Research grant/Funding (institution): Alkermes; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Blueprint; Research grant/Funding (institution): Corvus; Research grant/Funding (institution): Lycera; Research grant/Funding (institution): Merus; Research grant/Funding (institution): Molecular Partners; Research grant/Funding (institution): Rain Therapeutics; Research grant/Funding (institution): RAPT; Research grant/Funding (institution): Spectrum; Research grant/Funding (institution): Turning Point Therapeutics. L.C. Villaruz: Advisory/Consultancy: Achilles; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Exelixis; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Rain Therapeutics; Research grant/Funding (institution): GSK. V.H.F. Lee: Honoraria (self): AstraZeneca; Advisory/Consultancy: AstraZeneca; Research grant/Funding (self): BMS; Research grant/Funding (self): Merck Sharp & Dohme; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Novartis. V.W. Zhu: Honoraria (self): AstraZeneca; Honoraria (self): Roche-Foundation Medicine; Honoraria (self): Roche / Genentech; Honoraria (self): Takeda; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Roche / Genentech; Advisory/Consultancy: Takeda; Advisory/Consultancy: TP Therapeutics; Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Roche-Foundation Medicine; Speaker Bureau/Expert testimony: Roche / Genentech; Speaker Bureau/Expert testimony: Takeda; Shareholder/Stockholder/Stock options: TP Therapeutics. C.S. Baik: Advisory/Consultancy: AstraZeneca; Research grant/Funding (institution): Calgene Inc.; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): SWOG; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Loxo Oncology; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Spectrum Pharmaceuticals; Research grant/Funding (institution): BluePrint Medicines; Research grant/Funding (institution): Daiichi Sankyo Inc; Research grant/Funding (institution): Rain Therapeutics; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): TP Therapeutics; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Lilly Oncology. A. Sacher: Honoraria (self): AstraZeneca; Honoraria (self): Merck; Honoraria (self): Genentech-Roche; Honoraria (self): Kisoli; Honoraria (self): BMS; Honoraria (self): Bayer; Honoraria (self): Tesaro; Honoraria (self): Pfizer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Merck; Advisory/Consultancy: Genentech-Roche; Advisory/Consultancy: Kisoli; Advisory/Consultancy: BMS; Advisory/Consultancy: Bayer; Advisory/Consultancy: Pfizer. C.E. McCoach: Honoraria (self): Novartis; Honoraria (self): Guardant health; Advisory/Consultancy: Genentech; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Revolution Medicines; Travel/Accommodation/Expenses: Lilly; Travel/Accommodation/Expenses: Takeda. D. Nguyen: Full/Part-time employment: Pacific Shores Medical Group. J.Y-C. Li: Advisory/Consultancy: Roche Hong Kong; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Foundation Medicine; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Lilly Oncology; Advisory/Consultancy: Merck; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis; Advisory/Consultancy: Takeda; Advisory/Consultancy: MSD; Research grant/Funding (self): Roche Hong Kong; Travel/Accommodation/Expenses: Roche Hng Kong; Travel/Accommodation/Expenses: Taiho; Travel/Accommodation/Expenses: Eisai; Travel/Accommodation/Expenses: Sanomic & xcelom; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Mundipharma. J.M. Pacheco: Honoraria (self): Takeda; Honoraria (self): Genentech; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Gerson Lehrman Group; Advisory/Consultancy: Hengrui Pharmaceuticals; Advisory/Consultancy: Jazz Pharmaceuticals; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda; Research grant/Funding (institution): Pfizer; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Takeda. C. Kim: Advisory/Consultancy: Novartis; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Regeneron; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Karyopharm; Research grant/Funding (institution): Debiopharm; Research grant/Funding (institution): Altor Bioscience. T.F. Burns: Advisory/Consultancy: Novartis; Advisory/Consultancy: Blueprint Medicine; Advisory/Consultancy: Thermo Fisher Scientific. E.L. Schenk: Honoraria (self): Medscape; Honoraria (self): Physician’s Education Resource; Advisory/Consultancy: AbbVie; Speaker Bureau/Expert testimony: Takeda; Speaker Bureau/Expert testimony: Roche; Full/Part-time employment: Practice Update. N. Leighl: Honoraria (self): MSD; Honoraria (self): BMS; Research grant/Funding (institution): Guardant Health; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Array; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): MSD. L. Tozzi: Shareholder/Stockholder/Stock options: Rain Therapeutics; Full/Part-time employment: Rain Therapeutics. D.R. Camidge: Advisory/Consultancy: Anchiarno; Advisory/Consultancy: Amgen; Advisory/Consultancy: Takeda; Advisory/Consultancy: Roche/Genentech; Advisory/Consultancy: EMD Serono; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Pfizer; Advisory/Consultancy: CBT Pharmaceuticals; Advisory/Consultancy: Achilles; Advisory/Consultancy: Daiichi-Sankyo; Advisory/Consultancy: G1 Therapeutics; Advisory/Consultancy: AbbVie; Advisory/Consultancy: Bio-Thera; Advisory/Consultancy: Blueprint; Advisory/Consultancy: BeyondSpring; Advisory/Consultancy: Apollomics; Advisory/Consultancy: 14ner/Elevation; Advisory/Consultancy: Archer; Advisory/Consultancy: Helssin; Advisory/Consultancy: BMS; Advisory/Consultancy: Lilly; Advisory/Consultancy: Medtronic; Advisory/Consultancy: Ribon; Leadership role: AbbVie; Leadership role: AstraZeneca; Leadership role: BMS; Leadership role: GSK; Leadership role: Hanosh; Leadership role: Inhibrx; Leadership role: Lycera.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings